Moderna Stock Slips Despite Recent Gains; Analysts Cautiously Optimistic Amid Expected Earnings Decline
• Moderna (MRNA) stock dropped 0.65% despite market gains, underperforming the S&P 500, Dow, and Nasdaq • MRNA has gained 41.18% over the past month, outpacing the Medical sector and S&P 500 • Analysts expect MRNA's next earnings report to show a year-over-year decline in EPS and revenue • Positive estimate revisions signal analysts' confidence in MRNA's business performance and profit potential • MRNA currently has a Zacks Rank of #3 (Hold) and is part of the Medical - Biomedical and Genetics industry grouped in the top 29% of Zacks industries